Scientists engineer CRISPR enzymes that evade immune system
The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...
TLE6 identified as a protein associated with infertility in male mice
Genetic changes are a significant cause of infertility, impacting over 15% of the global population. TLE6, a major protein ...
News Medical3d
CRISPR/Cas protein production made easy
In gene and cell therapy, RNP-mediated CRISPR gene editing is quickly emerging as the new norm. For many gene editing firms, GenScript has created hundreds of Cas9, Cas12a, Cas13a, MAD7 ...
CRISPR therapy corrects muscular dystrophy mutations and regrows muscles in mice
Researchers at the Experimental and Clinical Research Center (ECRC), a joint institution of the Max Delbrück Center and ...
Hosted on MSN2d
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...
EurekAlert!13d
Developing a CRISPR therapy for muscular dystrophy
Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...
Check Out What Whales Are Doing With CRSP
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...
foodengineeringmag3d
Understanding the Regulatory Challenges for CRISPR Gene Editing on Crops
CRISPR gene-editing technology presents a possible solution for feeding a growing population, but incorporating CRISPR into ...
pharmaphorum9d
CRISPR biotech Intellia cuts staff as it eyes 2027 launch
In October, Intellia reported phase 2 results with NTLA-2002 – which is pitching to become the first approved in vivo CRISPR ...
Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Editas Medicine (EDIT – Research Report) yesterday and set a ...
New gene-editing treatment extends lifespan in mice with prion disease
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends lifespan by about 50 percent in a mouse model of the fatal ...